SORRENTO Aktie

 >SORRENTO Aktienkurs 
6.25 EUR    +3.6%    (Tradegate)
Ask: 6.31 EUR / 2400 Stück
Bid: 6.24 EUR / 2500 Stück
Tagesumsatz: 8309 Stück
Realtime Kurs von 8 bis 22 Uhr!
>SORRENTO Performance
1 Woche: -14,4%
1 Monat: -30,6%
3 Monate: -5,0%
6 Monate: +169,0%
1 Jahr: +313,1%
laufendes Jahr: +93,7%
>SORRENTO Aktie
Name:  SORRENTO THER.NEW DL-0001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US83587F2020 / A1W8DY
Symbol/ Ticker:  8STN (Frankfurt) / SRNE (NASDAQ)
Kürzel:  FRA:8STN, 8STN.F, 8STN:GR, NASDAQ:SRNE
Index:  -
Webseite:  https://sorrentotherapeut..
Marktkapitalisierung:  1790 Mio. EUR
Umsatz:  30.25 Mio. EUR
EBITDA:  -146.6 Mio. EUR
Gewinn je Aktie:  -1.396 EUR
Schulden:  187.96 Mio. EUR
Liquide Mittel:  20.76 Mio. EUR
Umsatz-/ Gewinnwachstum:  39.10% / -
KGV/ KGV lG:  - / 2.33
KUV/ KBV/ PEG:  39.86 / 15.32 / -
Gewinnm./ Eigenkapitalr.:  - / -443.24%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Suchwörter:  SORRENTO
Letzte Datenerhebung:  28.10.20
>SORRENTO Eigentümer
Aktien: 261.74 Mio. St.
f.h. Aktien: 182.14 Mio. St.
Insider Eigner: 34.21%
Instit. Eigner: 17.86%
Leerverk. Aktien: 27.98%
>SORRENTO Peer Group

 
26.10.20 - 23:49
Sorrento Therapeutics (SRNE) Dips More Than Broader Markets: What You Should Know (Zacks)
 
In the latest trading session, Sorrento Therapeutics (SRNE) closed at $7.92, marking a -1.98% move from the previous day....
25.10.20 - 12:07
Is Sorrento Therapeutics Stock a Buy? (Fool)
 
Sorrento's coronavirus pipeline could still turn out to be a major disappointment....
22.10.20 - 13:25
Is Sorrento Therapeutics a Ticking Time Bomb for Investors? (Fool)
 
Its pipeline is full of exciting coronavirus treatment and vaccine candidates, but those don't justify Sorrento's stock price....
19.10.20 - 19:49
Tests, Treatments, Vaccines: Sorrento Therapeutics Is All In on COVID-19 (Fool)
 
Will the lack of focus be the biotech's downfall?...
17.10.20 - 12:13
Better Coronavirus Stock: Moderna vs. Sorrento Therapeutics (Fool)
 
Both biotechs have promising COVID-19 programs. But one is a much better pick at this point....
17.10.20 - 00:49
Why Sorrento Therapeutics Stock Cratered on Friday (Fool)
 
The loss-making company is opening its wallet for a complementary new asset....
16.10.20 - 01:19
Sorrento CEO discusses the latest on its coronavirus antibody treatment and rapid saliva test (CNBC)
 
Sorrento Therapeutics CEO Henry Ji joined CNBC's Jim Cramer on Thursday....
15.10.20 - 15:25
Brazil Healthcare Regulator Authorizes Sorrento Therapeutics′ Phase 2 Trial for Coronavirus Drug Candidate (Fool)
 
The American biotech aims to recruit 400 people for the study....
14.10.20 - 19:04
Sorrento Therapeutics down following R&D investor update on COVID-19 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
14.10.20 - 18:07
Why Sorrento Therapeutics Is Tanking Today (Fool)
 
The biotech's COVID-19 pipeline update isn't sitting well with shareholders today....
14.10.20 - 18:00
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics′ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients (GlobeNewswire EN)
 
SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 clinical trial of Abivertinib in mi...
14.10.20 - 14:22
Sorrento Therapeutics, Ocular Therapeutix among major healthcare premarket losers′ pack (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.10.20 - 21:34
Sorrento Therapeutics awarded antibodies patents (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.10.20 - 02:07
Sorrento Therapeutics Adds Another COVID-19 Treatment to Its Pipeline (Fool)
 
The company's pipeline is large. Its list of FDA-authorized drugs is nonexistent....
>Zitat des Tages: Wie respektabel die Leut′ sind, das soll man nie auf′n ersten Blick beurteil′n, weil man sich beim zweiten nur zu oft vom Gegenteil überzeugt. - Johann Nepomuk Nestroy
Partner:    >Tradegate Börse | >TraderFox Handelssignale | >Heibel-Ticker Börsenbrief | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf Twitter

Copyright @ Boersentreff.de - Die Märkte im Blick!